Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
about
Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab.A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis.Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational studyEarly Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate.Genetic and genomic predictors of anti-TNF response.Current treatments of rheumatoid arthritis: from the 'NinJa' registry.Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease.Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients.Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of theRationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis.Effects of anti-IL-6 receptor antibody on human monocytes.What is the future of CCR5 antagonists in rheumatoid arthritis?Viewpoint on handling anti-TNF failure in psoriasis.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases.Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.Effects of CTLA4-Ig on human monocytes.Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease.CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents.Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.Adalimumab concentration-based tapering strategy: as good as the recommended dosage.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis.Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression.Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritRadiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis.
P2860
Q27692641-7DBCF220-A7DF-451C-B51C-4E5094B206F5Q31090628-F8BA051F-FAFF-488A-8770-1D7D2D2970C2Q35913704-B68FA70D-F54F-42D9-AEAE-29700B17DCC9Q37023883-A66DE9A0-6B30-41CF-8509-8576BE9D2A4AQ37111423-CEB21A04-83DA-47BC-9F3C-D0ED06339C77Q37208439-8689FC20-A4EC-49A2-BFEF-DAD59F574A14Q37951648-DD959493-6CD1-493F-9CEC-2BC5374C040BQ38033650-169E0B08-93CD-416D-9FB5-68DFE9D54294Q38116746-2B5F1C81-EE9E-4D39-BB17-71A303F7B4E8Q38176154-08A8B4F1-C3F7-49DB-B032-1D2469582D1CQ38364461-58818D23-FE18-4C7A-B716-E0FDCF90D0A3Q38501680-56E243B3-80AC-43BD-A0FA-14BD58B537F9Q38564877-1986B763-D238-4358-A5EF-A688DC28040FQ38714339-B1CF88E0-4CBD-4EF6-9A7C-2A95B17C8A45Q38822920-ABA6CAE1-3557-43D4-884E-FEC2AA1D2EC0Q38826447-04E6D9F6-3067-4158-A912-8379DD5652E1Q40039188-6AD1DA23-6793-402B-AAB8-DA67926A1093Q40040817-DF04C53A-A9B7-4E4A-A6C4-F3B3264901CFQ41482221-536CDB90-F8F3-4AD7-A375-EDBC45DA734DQ41595373-33AA572B-DE26-4185-9AEB-70739B4DF5B9Q42030573-A7C3F0F8-8F64-4374-8B9B-905E81694719Q42214646-02B54CE6-3B43-4820-BC9D-E2C670DD34DAQ42326321-B42350F2-66C0-4E8C-9518-3ADBC470180FQ43973219-2BEDF22E-4B3D-45F6-848D-63BA6DE7B762Q43988900-5DCC2B77-4689-47F9-A192-F6FDFC85398DQ45911203-C0542097-1A77-4762-ADC2-5BA9D9F705D8Q45938776-F5CC9E53-9FF1-4F32-BB4D-FCAEFD483E1BQ47098204-D2C34B17-6092-47D7-93F7-5F48D88BC6D0Q47163453-D65A7157-1CF0-4C46-9ED2-992F72597674Q47300233-C44FA923-9A92-4758-9EF1-1CE43B738A9EQ47662522-CBAB7B75-A80B-4B2E-BF02-75258C6D3DD9Q47805665-A9911F8B-3DBE-4BD1-AA31-5360AB742DCAQ47841198-83C3B907-648E-4AC4-8424-24DD90E69EDCQ48548520-76016578-6CE2-4C21-9829-3AA42EBFFB67Q50065301-F7E7B843-552D-42C6-85A7-13B2E6E949C0Q50082712-027B580B-062F-4613-838C-B40A71AE1EF8Q50919940-64B49D75-8729-4772-B8D0-D717D70E21ADQ51697159-60C22979-42D2-482F-B7EC-7C59ACCDCDA5Q52562516-05B55C43-A6BB-407C-884F-3D55999D1555Q53546741-0A5894DE-5F35-4B8C-9B2D-7508FB59DD86
P2860
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@ast
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@en
type
label
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@ast
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@en
prefLabel
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@ast
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Baseline tumour necrosis facto ...... nts with rheumatoid arthritis.
@en
P2093
Nobuyuki Miyasaka
Toru Yoshinari
Toshiro Yano
Tsutomu Takeuchi
Yoshihiko Tatsuki
P2860
P304
P356
10.1136/ARD.2011.153023
P407
P50
P577
2011-04-08T00:00:00Z